Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Initial data readout on track for second half of 2025HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...